

Annual Prior Authorization Review – Smoking Cessation Products Fiscal Year 2008

Oklahoma Health Care Authority
January 2009

Prior Authorization

- All smoking cessation products are covered, including OTC products with federal drug rebate agreements.
Dual eligible members are eligible only for OTC products.
- All smoking cessation products are covered without prior authorization for the first 90 days.
- After 90 days of use in a 365 day period, further use of smoking cessation products requires prior authorization.
- Criterion for approval of PA after the first 90 days of use: petition must state that the patient is enrolled in a smoking cessation behavior modification program.
- Length of approval: PA can be approved for another 90 days.
- After the patient has had 180 days of treatment in a 365 day period, the patient must wait another 180 days before smoking cessation treatment will be covered again.
- Smoking cessation products do not count against either the 6 prescription per month limit or the 3 branded drugs per month limit.

Utilization Fiscal Year 2008

For the period of July 2007 through June 2008, a total of **7,951** members received smoking cessation products through the SoonerCare fee-for-service program.

Total Cost FY '08	\$1,523,625.03	↑23.1%
	<i>Total Cost FY '07</i>	\$1,237,851.83
Total Claims FY '08	14,964	↑10.7%
	<i>Total Claims FY '07</i>	13,367
Per Diem FY '08	\$3.72	↑6.6%
	<i>Per Diem FY '07</i>	\$3.50
Total Members FY '08*	7,951	↑8.5%
<small>*unduplicated</small>	<i>Total Members FY '07*</i>	7,277

Nicotine Replacement Therapy and Antidepressant Products

Product	# of Claims	Total Units	Total Days	Claims/Member	Total Cost	Total Members	Per Diem
Zyban	180	10,220	5,421	1.5	\$9,139.47	118	\$1.69
Spray	14	380	331	2	\$1,423.21	7	\$4.30
Inhalers	157	28,528	3,870	1.44	\$25,747.13	109	\$6.65
Patches	2,677	64,060	62,753	1.39	\$227,969.47	1,918	\$3.63
Gum	253	51,074	5,319	2.13	\$22,182.04	119	\$4.17
Lozenges	99	10,950	1,421	2.5	\$5,499.58	40	\$3.87
Chantix	11,584	623,519	330,846	1.3	\$1,131,664.13	9,035	\$3.42
Total	14,964	788,731	409,961	1.88	\$1,523,625.03	7,951*	\$3.72

*Total unduplicated members for FY'08


% Change versus FY'07		
Product	Claims	Total Cost
Zyban (ea)	(-25)	(-44.85)
Spray (ml)	36	(-8.33)
Inhalers (cart)	(-54)	(-47.94)
Patches (ea)	(-38.77)	(-37.02)
Gum (ea)	(-16.22)	15.81
Lozenges (ea)	(-43)	(-44.27)
Chantix	33.74	33.1

Total petitions received for this category FY '08 vs. FY '07: 1,423 (950)

Approved	324 (163)
Denied	567 (550)
Incomplete	528 (225)

Demographics

Claims were reviewed to determine the age/gender of the members.



Age	Female	Male	Totals
0 to 9	2	8	10
10 to 19	187	131	318
20 to 34	1,736	285	2,021
35 to 49	2,151	620	2,771
50 to 64	1,653	720	2,373
65 to 79	170	104	274
80 to 94	11	5	16
95 and Over	1	1	2
Totals	5,371	1,906	7,277

Current News:

NABI Biopharmaceuticals has an investigational vaccine called NicVAX[®] (Nicotine Conjugate Vaccine) in phase 2b study to treat nicotine addiction and prevent smoking relapse. It is designed to stimulate the immune system and make antibodies in the bloodstream that bind to nicotine and keep it from crossing the blood-brain barrier.

Recommendations:

The College of Pharmacy recommends continued monitoring and evaluation of the cost and utilization of this Prior Authorization category.